Peripheral neuropathies: Subcutaneous immunoglobulin - the future of CIDP treatment?

Nat Rev Neurol. 2018 Mar;14(3):130-131. doi: 10.1038/nrneurol.2017.179. Epub 2018 Jan 12.

Authors

Benjamin R Wakerley¹, Nobuhiro Yuki²

Affiliations

¹ Department of Neurology, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK; and at the Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Headley Way, OX3 9DU, Oxford, UK.
² Department of Medicine, Eda Memorial Hospital, Azamino-minami 1-1-1, Aoba-ku, Yokohama, Kanagawa, 225-0012, Japan.

PMID: 29326423
DOI: 10.1038/nrneurol.2017.179

No abstract available

Publication types

News

MeSH terms

Administration, Cutaneous
Humans
Immunoglobulins / administration & dosage
Immunoglobulins / pharmacology*
Immunologic Factors / administration & dosage
Immunologic Factors / pharmacology*
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
Treatment Outcome

Substances

Immunoglobulins
Immunologic Factors

Grants and funding

G0501747/MRC_/Medical Research Council/United Kingdom